Clinical Scorecard: Successful Management of Refractory Immune Cytopenia with Mycophenolate Mofetil in Four Adolescents Diagnosed with 22q11.2 Deletion Syndrome
At a Glance
Category
Detail
Condition
Refractory Immune Thrombocytopenia (ITP) in 22q11.2 Deletion Syndrome
Key Mechanisms
Immunodysregulation with diminished naïve CD4+ T cells and memory B cells, increased cTfh cells, and decreased Treg cells.
Target Population
Pediatric/adolescent patients with 22q11.2 deletion syndrome and refractory ITP.
Care Setting
Pediatric care at a specialized children's hospital.
Key Highlights
All four patients achieved prolonged platelet stabilization with low-dose Mycophenolate Mofetil (MMF).
Three out of four patients reached complete remission with platelet counts > 100,000/uL.
Immunological biomarkers were tracked to evaluate treatment response.
No relapses were reported during the 24-month treatment period.
MMF was effective as a second-line treatment for resistant autoimmune cytopenia.
Guideline-Based Recommendations
Diagnosis
Diagnosis of ITP based on platelet count and absence of hemorrhage.
Management
First-line treatment includes high-dose intravenous immunoglobulins (IVIg); second-line options include steroids, MMF, sirolimus, TPOR agonists, and Rituximab.
Monitoring & Follow-up
Monitor platelet counts and immunological parameters during treatment.
Risks
Potential for relapse and complications associated with underlying immune dysregulation.
Patient & Prescribing Data
Adolescents with 22q11.2 deletion syndrome experiencing refractory ITP.
Low-dose MMF effectively stabilized platelet counts and improved immunological profiles.
Clinical Best Practices
Utilize immunological biomarkers to guide treatment decisions.
Conduct regular monitoring of platelet counts and immune function.
Consider MMF as a second-line treatment for refractory ITP in this population.
